CXCR3 ligands promote expression of functional indoleamine 2,3-dioxygenase in basal cell carcinoma keratinocytes

British Journal of Dermatology

Volumn 165, Issue 5, 2011, Pages 1030-1036

  Lo, B K K ^a   Jalili, R B ^a   Zloty, D ^b   Ghahary, A ^a   Cowan, B ^b   Dutz, J P ^a,b   Carr, N ^c   Shapiro, J ^b   McElwee, K J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; CYTOKERATIN 17; INDOLEAMINE 2,3 DIOXYGENASE; COMPLEMENTARY DNA; CXCR3 PROTEIN, HUMAN; KYNURENINE; RNA;

ARTICLE; BASAL CELL CARCINOMA; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; ENZYMOLOGY; FEMALE; MALE; METABOLISM; PHYSIOLOGY; SKIN TUMOR; TUMOR CELL CULTURE;

CARCINOMA, BASAL CELL; DNA, COMPLEMENTARY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KERATINOCYTES; KYNURENINE; MALE; RECEPTORS, CXCR3; RNA; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84856368231     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10489.x     Document Type: Article

References (31)

1. Kyrgidis A, Tzellos TG, Vahtsevanos K et al. New concepts for basal cell carcinoma. Demographic, clinical, histological risk factors, and biomarkers. A systematic review of evidence regarding risk for tumor development, susceptibility for second primary and recurrence. J Surg Res 2010; 159:545-56.
2. Kaur P, Mulvaney M, Carlson JA. Basal cell carcinoma progression correlates with host immune response and stromal alterations: a histologic analysis. Am J Dermatopathol 2006; 28:293-307. (Pubitemid 44181566)
3. Walling HW, Fosko SW, Geraminejad PA et al. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev 2004; 23:389-402. (Pubitemid 38881820)
4. Huang L, Baban B, Johnson BA III et al. Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. Int Rev Immunol 2010; 29:133-55.
5. Uyttenhove C, Pilotte L, Theate I et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9:1269-74. (Pubitemid 37279849)
6. Fallarino F, Grohmann U, Vacca C et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002; 9:1069-77.
7. Furuya M, Suyama T, Usui H et al. Up-regulation of CXC chemokines and their receptors: implications for proinflammatory mic-roenvironments of ovarian carcinomas and endometriosis. Hum Pathol 2007; 38:1676-87. (Pubitemid 47589091)
8. Lo BK, Yu M, Zloty D et al. CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas. Am J Pathol 2010; 176:2435-46.
9. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001; 25:402-8. (Pubitemid 34164012)
10. Alessi E, Venegoni L, Fanoni D et al. Cytokeratin profile in basal cell carcinoma. Am J Dermatopathol 2008; 30:249-55.
11. Asada M, Schaart FM, de Almeida HL Jr et al. Solid basal cell epithelioma (BCE) possibly originates from the outer root sheath of the hair follicle. Acta Derm Venereol (Stockh) 1993; 73:286-92. (Pubitemid 23282976)
12. Kurzen H, Esposito L, Langbein L et al. Cytokeratins as markers of follicular differentiation: an immunohistochemical study of trichoblastoma and basal cell carcinoma. Am J Dermatopathol 2001; 23:501-9. (Pubitemid 33086477)
13. Schirren CG, Rutten A, Kaudewitz P et al. Trichoblastoma and basal cell carcinoma are neoplasms with follicular differentiation sharing the same profile of cytokeratin intermediate filaments. Am J Dermatopathol 1997; 19:341-50. (Pubitemid 27467159)
14. Apaydin R, Gurbuz Y, Bayramgurler D et al. Cytokeratin contents of basal cell carcinoma, epidermis overlying tumour, and associated stromal amyloidosis: an immunohistochemical study. Amyloid 2005; 12:41-7. (Pubitemid 40896943)
15. Yoshikawa K, Katagata Y, Kondo S. Biochemical and immunohisto-chemical analyses of keratin expression in basal cell carcinoma. J Dermatol Sci 1998; 17:15-23. (Pubitemid 28253042)
16. Forouzandeh F, Jalili RB, Germain M et al. Skin cells, but not T cells, are resistant to indoleamine 2,3-dioxygenase (IDO) expressed by allogeneic fibroblasts. Wound Repair Regen 2008; 16:379-87. (Pubitemid 351661576)
17. Sarkhosh K, Tredget EE, Uludag H et al. Temperature-sensitive polymer-conjugated IFN-gamma induces the expression of IDO mRNA and activity by fibroblasts populated in collagen gel (FPCG). J Cell Physiol 2004; 201:146-54. (Pubitemid 39187053)
18. Li Y, Tredget EE, Ghaffari A et al. Local expression of indoleamine 2,3-dioxygenase protects engraftment of xenogeneic skin substitute. J Invest Dermatol 2006; 126:128-36. (Pubitemid 43336104)
19. Vargo N. Basal cell and squamous cell carcinoma. Semin Oncol Nurs 2003; 19:12-21. (Pubitemid 40941060)
20. Wong CS, Strange RC, Lear JT. Basal cell carcinoma. BMJ 2003; 327:794-8. (Pubitemid 37211176)
21. Munn DH, Shafizadeh E, Attwood JT et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189:1363-72. (Pubitemid 29227522)
22. Sun T, Chen XH, Tang ZD et al. Novel 1-alkyl-tryptophan derivatives downregulate IDO1 and IDO2 mRNA expression induced by interferon-gamma in dendritic cells. Mol Cell Biochem 2010; 342:29-34.
23. Witkiewicz AK, Costantino CL, Metz R et al. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg 2009; 208:781-7.
24. Hwu P, Du MX, Lapointe R et al. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 2000; 164:3596-9. (Pubitemid 30169812)
25. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999; 20:469-73. (Pubitemid 29476077)
26. Munn DH, Zhou M, Attwood JT et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281:1191-3. (Pubitemid 28406294)
27. Meyer KC, Klatte JE, Dinh HV et al. Evidence that the bulge region is a site of relative immune privilege in human hair follicles. Br J Dermatol 2008; 159:1077-85.
28. Ball HJ, Yuasa HJ, Austin CJ et al. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int J Biochem Cell Biol 2009; 41:467-71.
29. Metz R, Duhadaway JB, Kamasani U et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the anti-tumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 2007; 67:7082-7. (Pubitemid 47206533)
30. Hou DY, Muller AJ, Sharma MD et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007; 67:792-801. (Pubitemid 46192220)
31. von Bubnoff D, Bausinger H, Matz H et al. Human epidermal Langerhans cells express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. J Invest Dermatol 2004; 123:298-304. (Pubitemid 38951824)